Text Messaging for Leukemia

Overseen By Clinical Trials Intake

Age: < 65

Sex: Any

Trial Phase: Academic

Sponsor: University of Chicago

Must be taking: Mercaptopurine, Methotrexate

Disqualifiers: No cell phone, Does not wish

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

38 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this section is to learn how text message reminders might help with regularly taking chemotherapy medications for Adolescents and Young Adults (AYA) with Acute Lymphoblastic leukemia (ALL).

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, it requires participants to be on a specific treatment regimen that includes mercaptopurine and methotrexate.

How does the text messaging treatment for leukemia differ from other treatments?

The text messaging treatment for leukemia is unique because it likely involves using digital communication to support patients, which is different from traditional medical treatments like chemotherapy or immunotherapy. This approach may focus on enhancing patient engagement and adherence to treatment plans rather than directly targeting leukemia cells. ^{1 2 3 4 5}

Research Team

Wendy Stock, MD

Principal Investigator

University of Chicago

Eligibility Criteria

This trial is for young people aged 15-39 who were diagnosed with Acute Lymphoblastic Leukemia (ALL) and are starting maintenance treatment that includes mercaptopurine and methotrexate. They must want to participate and have a cell phone capable of receiving text messages.

Inclusion Criteria

I have been diagnosed with Acute Lymphoblastic Leukemia (ALL).

I was diagnosed with ALL between the ages of 15 and 39.

I am starting maintenance treatment with mercaptopurine and methotrexate.

Exclusion Criteria

I do not want to join the clinical trial.

Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive oral mercaptopurine and methotrexate with text message interventions to improve adherence during the first 84-day cycle of maintenance therapy

12 weeks

Regular monitoring visits as per standard of care

Follow-up

Participants are monitored for safety, effectiveness, and clinical outcomes after the treatment phase

1 year

Treatment Details

Interventions

• Text Messages

Trial Overview The study tests if text message reminders can help adolescents and young adults take their oral chemotherapy medications more consistently. Participants will receive either high intensity, low intensity, or no text messaging as part of the intervention.

Participant Groups

Group I: High Intensity Active Control 1 Intervention

Receives high-intensity text messaging for 2 cycles of treatment

Group II: Low Intensity Active Control 2 Interventions

Receives no texts for 1st cycle and low-intensity texts for 2nd cycle

Who Is Running the Clinical Trial?

University of Chicago

Lead Sponsor

Trials

1,086

Recruited

844,000+

References

1. Japan pubmed.ncbi.nlm.nih.gov

Immune and cell therapy of hematologic malignancies. [2019]

2. United States pubmed.ncbi.nlm.nih.gov

Controversies in the therapy of acute myelogenous leukemia. [2019]

3. England pubmed.ncbi.nlm.nih.gov

Immunotherapeutic peptide vaccination with leukemia-associated antigens. [2020]

4. England pubmed.ncbi.nlm.nih.gov

Novel therapy for childhood acute lymphoblastic leukemia. [2018]

5. Germany pubmed.ncbi.nlm.nih.gov

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. [2014]